Fintel reports that on March 25, 2025, William Blair initiated coverage of Immunic (NasdaqGS:IMUX) with a Outperform ...

Analysts are intrested in these 5 stocks: ( ($IMUX) ), ( ($X) ), ( ($KLAC) ), ( ($IIPR) ) and ( ($GT) ). Here is a breakdown ...

Immunic, Inc. (NASDAQ:IMUX – Get Free Report) has received a consensus rating of “Buy” from the nine brokerages that are ...

Equities researchers at Leerink Partnrs dropped their Q1 2025 earnings estimates for Immunic in a research note issued on Tuesday, April 1st. Leerink Partnrs analyst F. Khurshid now expects that the ...

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today ...

Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases.

Immunic (IMUX – Research Report) received a Buy rating and a $1.20 price target from William Blair analyst Matt Phipps yesterday. The company’s ...

Immunic, Inc. (NASDAQ: IMUX) shares are roughly flat following strength early Friday after the company announced a three-tranche private placement of up to $240 million.

Short interest in Immunic Inc (NASDAQ:IMUX) decreased during the last reporting period, falling from 2.55M to 2.40M. This put 2.69% of the company's publicly available shares short. Short interest ...

Immunic, Inc. to Participate in Scientific and Industry Conferences in April ...

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...